In April 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. The public comment period closes June 29, 2026. If this proposal goes final, outsourcing facilities — the large-scale compounding pharmacies that supply most telehealth platforms with compounded GLP-1 medications — lose their legal basis for producing these drugs.

Novo Nordisk estimated that 1.5 million Americans are currently using compounded GLP-1s. Every single one of them may need to transition to FDA-approved alternatives if this rule takes effect.

1.5 Million
Estimated Americans on compounded GLP-1s who may need to transition

What the 503B Bulks List Is — And Why It Matters

Federal law creates two categories of compounding pharmacies, and understanding the difference is essential to understanding what's at stake.

503A pharmacies are traditional compounding pharmacies that prepare medications based on individual patient prescriptions. They operate under state pharmacy board oversight and compound patient-specific formulations. Under 503A, a pharmacy can compound semaglutide for a specific patient with a valid prescription when there's a documented clinical need — even if the drug isn't on a shortage list.

503B outsourcing facilities are registered with the FDA and can produce compounded medications in larger batches without patient-specific prescriptions. This is what enables telehealth platforms to offer "compounded semaglutide" at scale — the outsourcing facility manufactures large quantities, and the telehealth platform matches them to patients.

The 503B Bulks List determines which drug substances outsourcing facilities can use. If semaglutide, tirzepatide, and liraglutide are removed from this list, 503B facilities can no longer legally produce them in bulk. Only 503A patient-specific compounding with documented clinical need survives — and that model cannot support the volume that telehealth platforms currently move.

Featured Provider
Embody
Injectable semaglutide programs with clinical oversight
Embody provides injectable semaglutide programs. Verify medication sourcing with any provider.
Learn More About Embody →
Paid link · Advertising disclosure

The Timeline of the Compounding Crackdown

The 503B proposal didn't emerge in a vacuum. It's the latest step in an escalating enforcement trajectory:

Each step narrows the legal window for mass compounding. The 503B proposal, if finalized, effectively closes it.

What Still Survives Under 503A

The proposal doesn't eliminate all compounding. 503A patient-specific compounding remains legal where there's a documented clinical need — meaning a prescriber determines that the commercially available product doesn't meet a specific patient's medical requirements (allergy to an inactive ingredient, need for a different concentration or delivery method, etc.).

But "it's cheaper" is not a clinical need. "The patient prefers compounded" is not a clinical need. The standard is narrower than most consumers realize, and state pharmacy boards are increasingly scrutinizing whether clinical need documentation meets the regulatory threshold.

Key Takeaway: The entire compounded GLP-1 telehealth market was built on a temporary regulatory exception during drug shortages. That exception is being systematically closed. If you're currently on compounded semaglutide or tirzepatide, the prudent move is to understand your transition options now — before your current supply chain is disrupted.

Your Transition Options

If you're currently on compounded GLP-1 medications through a telehealth platform, here's how to prepare:

  1. Check your insurance. Commercial plans increasingly cover branded Wegovy and Zepbound. The cost gap between compounded and insured-branded may be smaller than you think.
  2. Explore the Medicare Bridge. If you're a Medicare beneficiary, the $50/month Bridge program launches July 1, 2026 for brand-name GLP-1s.
  3. Review manufacturer savings programs. Novo Nordisk and Eli Lilly both offer savings cards that can reduce brand-name costs to $25-50/month for eligible patients.
  4. Ask your telehealth provider about their contingency plan. Responsible platforms should already have a transition strategy. If they don't, or won't share it, consider that a red flag.
  5. Don't wait for the disruption. Supply chain transitions are smoother when they're planned than when they're forced by a regulatory deadline.
Sesame Care
Brand-name FDA-approved GLP-1 prescriptions
Sesame Care provides access to brand-name, FDA-approved GLP-1 medications only.
Sesame Care provides access to brand-name, FDA-approved GLP-1 medications — no compounding involved.
Visit Sesame Care → Paid link
FeelGood Telehealth
$149/mo injections, LegitScript-certified telehealth
LegitScript-certified with multiple medication sourcing options. Ask about their branded alternatives.
Visit FeelGood Telehealth → Paid link
FDA Compounding Disclaimer: Compounded medications are not FDA-approved. They are prepared by compounding pharmacies based on individual prescriptions. The FDA does not verify the safety, efficacy, or quality of compounded drugs. Patients should discuss the risks and benefits with their prescriber.
Related Articles
Is GLP-1 Telehealth Safe? What the Research Shows →How to Verify if a GLP-1 Telehealth Provider Is Legitimate →Best GLP-1 Telehealth Platforms in 2026 →
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a licensed healthcare provider before starting, stopping, or changing any medication. GLP-1 receptor agonists carry risks including but not limited to gastrointestinal side effects, pancreatitis, gallbladder disease, and thyroid concerns. Individual results vary. This site contains affiliate links — see our advertising disclosure for details.